PT-141 (Bremelanotide): How It Works and Its Approval Status

PT-141 and bremelanotide are two names for the same molecule, but they sit in very different regulatory worlds. As Vyleesi, bremelanotide is genuinely FDA-approved, for one specific indication: hypoactive sexual desire disorder (HSDD) in premenopausal women. As PT-141, sold or compounded for off-label use including in men, it is the same molecule outside the approved product and indication, which is not FDA-approved. It works centrally in the brain on melanocortin receptors, and any use should be provider-directed.

This article explains how bremelanotide works, the all-important approved-versus-off-label distinction, the evidence, and the side-effect profile. It is not a dosing guide or a recommendation to use it.

What bremelanotide is, and the two names

Bremelanotide is a synthetic peptide that activates melanocortin receptors. The naming is the first thing to get straight, because it is the source of most confusion:

• Vyleesi (bremelanotide injection) is an FDA-approved prescription drug. It was approved in June 2019 specifically for acquired, generalized HSDD in premenopausal women. It is supplied as a 1.75 mg subcutaneous auto-injector, taken about 45 minutes before anticipated sexual activity, not daily, with a maximum of one dose per 24 hours.
• PT-141 is the research and community name for the same molecule. Under that name it is used off-label, for men and women, sold as a compounded injectable or a research chemical, for purposes the approved product does not cover.

So unlike nearly every other compound in the peptide lane, this one has a real FDA approval at its core. That is genuinely unusual: most "other" peptides marketed for wellness, from semax to NAD+, are not approved for anything, whereas bremelanotide has been through the full FDA process for one use. The catch is that the approval is narrow, and most of the discussion online concerns uses that fall outside it.

The "research peptide" framing also tends to obscure that this is a pharmacologically serious drug, not a gentle supplement. It has a defined dose, a real side-effect profile, and meaningful contraindications, all of which are covered below. Treating PT-141 as a casual libido booster, the way it is sometimes sold, understates what it is.

How it works

Bremelanotide is a melanocortin receptor agonist, acting mainly on the MC3R and MC4R receptors in the central nervous system. This is the mechanistic feature that sets it apart from the better-known drugs for sexual function.

PDE5 inhibitors such as Viagra (sildenafil) and Cialis (tadalafil) act on the vasculature, improving blood flow to the penis to support an erection. They address the physical mechanics. Bremelanotide acts in the brain, on pathways involved in sexual desire itself. That is why it is positioned as a treatment for low desire rather than for the physical capacity for an erection, and why it is studied in HSDD, a desire disorder, rather than purely as an erectile-dysfunction drug.

This distinction is not academic, because it shapes what bremelanotide can and cannot do. A drug that acts on desire is being asked to influence a complex, multifactorial experience, one tangled up with relationship context, mood, medications, and physical health. That is a harder target than blood flow, and it helps explain why the measured effect in trials is modest rather than dramatic. It also explains why the approved indication is so carefully defined: HSDD is diagnosed only after relationship issues, other medications, and medical causes have been ruled out, precisely because so many things can dampen desire that are not a melanocortin-pathway problem.

Approved versus off-label: the comparison that matters

Because the same molecule lives in two regulatory contexts, a side-by-side is the clearest way to see the difference. This table contrasts the approved product with research-grade PT-141; it is not a guide to using either.

	Vyleesi (bremelanotide)	"PT-141" (research-grade / compounded)
Regulatory status	FDA-approved prescription drug	Not FDA-approved as used; compounded status depends on current rules
Approved indication	HSDD in premenopausal women	None; used off-label (men, postmenopausal women, ED)
Dose and form	Defined: 1.75 mg subcutaneous auto-injector	Variable; depends on source and prescriber
Quality assurance	Manufactured to FDA standards	Variable; research-chemical purity not guaranteed
Evidence base	Two large RCTs for the approved use	Limited published data for off-label uses

The crux is this: the molecule being FDA-approved does not make every use of it FDA-approved. Off-label prescribing is legal in the US, and clinicians do prescribe compounded bremelanotide, but that is different from the drug being studied, reviewed, and approved for that purpose.

What the evidence shows

For the approved indication, the evidence is real. FDA approval rested on two identical 24-week, double-blind, placebo-controlled randomized trials in 1,247 premenopausal women with HSDD. Roughly 25 percent of women on bremelanotide met the response threshold versus about 17 percent on placebo, an absolute difference of about 8 percentage points, which translates to a number-needed-to-treat of around 12 (FDA Vyleesi label; PMC HSDD review). That is a statistically significant but modest effect: it helps some women meaningfully, and many see little benefit.

For off-label uses, the evidence is thinner. Use for erectile dysfunction in men, or for sexual desire in postmenopausal women, has limited published data and has not been reviewed by the FDA for those indications. The honest framing is that the strong, approval-grade evidence applies to one specific population and use, and does not automatically transfer.

It is worth dwelling on what "modest effect" means here, because it is easy to read an FDA approval as a guarantee of a strong result. The roughly 8-percentage-point difference over placebo, with a number-needed-to-treat around 12, means that for every twelve women treated, about one experiences a meaningful benefit attributable to the drug rather than to placebo. That is a real effect, and for the woman it helps it can matter a great deal, but it is not the kind of near-universal response people sometimes assume. The high placebo response in these trials (around 17 percent) is itself a reminder of how much expectation contributes to outcomes in this area, which is one reason individual tracking, discussed below, is so useful for telling a genuine response from a hopeful one.

Side effects and the alcohol warning

Bremelanotide has a real, documented side-effect profile, and minimizing it would be irresponsible. From the Vyleesi trials:

• Nausea was common, around 40 percent versus 1 percent on placebo, and was the leading reason people stopped.
• Flushing (around 20 percent), injection-site reactions (around 13 percent), and headache (around 11 percent) were also frequent.
• Hyperpigmentation (skin darkening) can develop with repeated use.
• Transient blood-pressure increases occur, with a compensating heart-rate change.

Discontinuation for adverse events ran about 18 percent versus 2 percent on placebo, a meaningful gap. There are important cautions: it must not be used with alcohol, which raises the risk of dangerous drops in blood pressure, and it is cautioned against in people with high cardiovascular risk and may interact with blood-pressure medications. These are not trivial footnotes; they are reasons the drug is not for everyone and belongs under medical supervision.

What to ask a provider

Because bremelanotide is a real drug with a real side-effect burden, a provider conversation is the appropriate path. Useful questions:

• Is an HSDD diagnosis actually appropriate, after ruling out relationship factors, medications, and medical causes?
• Given the modest effect size, is the potential benefit worth the side-effect burden for me?
• For off-label use, have better-evidenced options (such as PDE5 inhibitors for erectile dysfunction in men) been considered first?
• Do my blood pressure, cardiovascular history, and current medications raise any flags?

Where Myo fits

Bremelanotide is taken episodically, before anticipated activity rather than on a fixed daily schedule, and it carries side effects worth watching, especially nausea and blood-pressure changes. For provider-directed use, Myo logs the timing and dose and lets you record any side effects, so the pattern is documented for your next clinical conversation rather than reconstructed from memory.

That documentation matters most when the effect is modest and individual, as it is here. Keeping side effects and responses tracked over several uses is how you and a clinician tell a genuine benefit from chance, and catch a side effect like a blood-pressure change before it becomes a problem.

The bottom line: bremelanotide is FDA-approved as Vyleesi for HSDD in premenopausal women, a real drug with modest, evidence-backed benefit and a notable side-effect profile. "PT-141" is the same molecule used off-label and outside that approval. The molecule's approval does not extend to every use, alcohol is a hard contraindication, and any use belongs with a provider.

References

• FDA. Vyleesi (bremelanotide) Prescribing Information (2019). https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/210557s000lbl.pdf
• Simon JA et al. Bremelanotide for HSDD: review of the RECONNECT trials. PMC. https://pmc.ncbi.nlm.nih.gov/articles/PMC8788464/
• Palatin Technologies. FDA Approves New Drug Application for Vyleesi (bremelanotide injection). https://palatin.com/press_releases/fda-approves-new-drug-application-for-vyleesi-bremelanotide-injection-2/